Similar Articles |
|
American Family Physician August 15, 2006 Morris, Hatcher & Reddy |
Digoxin Therapy for Heart Failure: An Update Digoxin therapy has long been used to treat heart failure; however, its effectiveness was not completely known until recently. Results of the Digitalis Investigation Group trial showed that adding digoxin to standard heart failure therapy had no effect on mortality. |
American Family Physician September 15, 2001 |
Guideline for the Management of Heart Failure Caused by Systolic Dysfunction: Part II. Treatment Treatment recommendations for patients with left ventricular systolic dysfunction... |
American Family Physician April 15, 2001 Robert E. Hoyt & Lester Shawn |
Reducing Readmissions for Congestive Heart Failure Hospital admission for congestive heart failure is extremely common and quite expensive, although it is frequently preventable... |
American Family Physician December 1, 2000 Assad Movahed |
Beta Blockers and Congestive Heart Failure Heart failure is a complex condition, and its treatment requires consideration of two separate goals: symptom relief and tertiary prevention... |
American Family Physician December 1, 2004 McConaghy & Smith |
Outpatient Treatment of Systolic Heart Failure Optimal outpatient treatment of systolic heart failure has three goals that should be pursued simultaneously: (1) control of risk factors for the development and progression of heart failure, (2) treatment of heart failure, and (3) education of patients. |
American Family Physician October 15, 2001 Katherine L. Margo |
Spironolactone in Left-Sided Heart Failure: How Does It Fit In? The familiar diuretic spironolactone has taken on new life as a treatment for left-sided congestive heart failure. More research is necessary to determine the order and combinations of spironolactone and other medications in slowing the progression of this disease... |
American Family Physician March 1, 2006 Satpathy et al. |
Diagnosis and Management of Diastolic Dysfunction and Heart Failure With early diagnosis and proper management the prognosis of diastolic dysfunction is more favorable than that of systolic dysfunction. Distinguishing diastolic from systolic heart failure is essential because the optimal therapy for one may aggravate the other. |
American Family Physician November 15, 2000 Tarik M. Ramahi |
Beta Blocker Therapy for Chronic Heart Failure Recent studies have shown that beta blocker therapy improves survival and reduces hospitalizations in patients who have chronic heart failure and left ventricular systolic dysfunction... |
American Family Physician December 1, 2000 William E. Chavey |
The Importance of Beta Blockers in the Treatment of Heart Failure Traditionally, beta blockers have been considered to be contraindicated in patients with heart failure. Recently, however, several large randomized, controlled mortality trials have been stopped early because of the effects of beta blockers... |
American Family Physician August 1, 2002 Daphne P. Bicket |
Using ACE Inhibitors Appropriately Although angiotensin-converting enzyme (ACE) inhibitors have documented clinical benefits in a variety of clinical situations, the disparity between the evidence from clinical trials and bedside medicine is well documented. |
American Family Physician June 1, 2004 Gutierrez & Blanchard |
Diastolic Heart Failure: Challenges of Diagnosis and Treatment The outcomes of ongoing clinical trials may provide much-needed information about diastolic heart failure to move from intuitive treatment to therapy based on evidence that matters: decreased morbidity and mortality and improved quality of life. |
American Family Physician October 15, 2000 Patricia A. Howard & Edward F. Ellerbeck |
Optimizing Beta-Blocker Use After Myocardial Infarction Although beta-adrenergic blockers can significantly reduce mortality after a myocardial infarction, these agents are prescribed to only a minority of patients... |
American Family Physician September 1, 2001 William E. Chavey |
Guideline for the Management of Heart Failure Caused by Systolic Dysfunction Part I: Guideline development, etiology and diagnosis... |
American Family Physician February 1, 2005 Dickerson & Gibson |
Management of Hypertension in Older Persons Antihypertensive therapy has been shown to reduce morbidity and mortality in older patients with elevated systolic or diastolic blood pressures. |
American Family Physician December 1, 2003 Lyle A. Siddoway |
Amiodarone: Guidelines for Use and Monitoring Amiodarone is a potent antiarrhythmic agent that is used to treat ventricular arrhythmias and atrial fibrillation. The drug prevents the recurrence of life-threatening ventricular arrhythmias and produces a modest reduction of sudden deaths in high-risk patients. |
Nursing June 2010 Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
Nursing February 2010 Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
American Family Physician July 15, 2002 Dana E. King |
Acute Management of Atrial Fibrillation: Part I. Rate and Rhythm Control Atrial fibrillation is the arrhythmia most commonly encountered in family practice. Initial treatment is directed at controlling the ventricular rate. Medical or electrical cardioversion to restore sinus rhythm is the next step in patients who remain in atrial fibrillation. |
American Family Physician June 15, 2002 A. Kesh Hebbar |
Management of Common Arrhythmias: Part II. Ventricular Arrhythmias and Arrhythmias in Special Populations Patients with established heart disease and premature ventricular complexes have a higher likelihood of developing ventricular tachycardia or fibrillation. |
American Family Physician November 15, 2002 Cynthia M. Williams |
Using Medications Appropriately in Older Adults Finding the right balance between too few and too many drugs will help ensure increased longevity, improved overall health, and enhanced functioning and quality of life for the aging population. |
American Family Physician November 1, 2003 Scow et al. |
Combination Therapy with ACE Inhibitors and Angiotensin-Receptor Blockers in Heart Failure This article reviews the literature and available evidence on the use of ACE inhibitors and angiotensin-receptor blockers in combination for the treatment of patients with congestive heart failure. |
Nursing June 2011 Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
American Family Physician December 1, 2004 Steven A. Dosh |
Diagnosis of Heart Failure in Adults The evaluation of symptomatic patients with suspected heart failure is directed at confirming the diagnosis, determining the cause, identifying concomitant illnesses, establishing the severity of heart failure, and guiding therapy. |
American Family Physician June 15, 2002 A. Kesh Hebbar |
Management of Common Arrhythmias: Part I. Supraventricular Arrhythmias Family physicians frequently encounter patients with symptoms that could be related to cardiac arrhythmias, most commonly atrial fibrillation or supraventricular tachycardias. |
American Journal of Nursing May 2009 Kristen J. Overbaugh |
Acute Coronary Syndrome Coronary artery disease, in which atherosclerotic plaque builds up inside the coronary arteries and restricts the flow of blood (and therefore the delivery of oxygen) to the heart, continues to be the number-one killer of Americans. |
Nurse Practitioner February 2011 Jennifer M. Belavic |
Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available. |
Nurse Practitioner February 2012 Jennifer M. Belavic |
Annual drug update 2011 in review Many new medications were approved throughout 2011. This article will cover a variety of drugs that will be useful in nurse practitioner practice |
Nursing March 2012 Daniel A. Hussar |
New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs. |
Nursing February 2009 Daniel A. Hussar |
New Drugs 09: Part 1 Learn about 10 new drugs, including nebivolol HCl, the newest beta-adrenergic blocking agent for hypertension. |
Nurse Practitioner August 2009 Linda A. Howe |
Pharmacogenomics and management of cardiovascular disease Prior to the completion of the Human Genome Project in 2003, individual responses to medications were usually termed idiosyncrasies. Ethnic differences were not usually seen as genetic variants, as is the case today. |
American Family Physician September 15, 2000 Vincent Morelli, M.D. & Roger J. Zoorob, M.D., M.P.H. |
Alternative Therapies: Part II. Congestive Heart Failure and Hypercholesterolemia Natural supplements are widely used by the American public but, while claims of their therapeutic effects abound, medical research does not always support their effectiveness... |
American Journal of Nursing November 2011 Christine L. Cutugno |
The 'Graying' of Trauma Care: Addressing Traumatic Injury in Older Adults Evidence-based strategies for managing trauma and its complications in this population. |
The Motley Fool September 7, 2010 Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
Nursing March 2010 Peg Gray-Vickrey |
Gathering pearls of knowledge for assessing older adults If you attended nursing school more than 10 years ago, you may have received limited education about gerontological nursing. But as baby boomers age, this is becoming an increasingly important area of nursing practice. |
Pharmaceutical Executive November 1, 2012 Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
The Motley Fool August 10, 2010 Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
Fast Company December 2009 Elizabeth Svoboda |
Biotechs Look Overseas to Launch a Stem-Cell Revolution According to one small biotech, the best way to launch a stem-cell revolution is to do it overseas. |
The Motley Fool September 8, 2010 Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
American Family Physician July 15, 2003 |
Heart Failure What is heart failure?... What causes heart failure?... What are the symptoms of heart failure?... What tests will I need?... What treatment will I need?... What medicines will I need to take?... etc. |
The Motley Fool August 11, 2010 Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
Pharmaceutical Executive November 1, 2012 Lauri Mitchell |
Who Pays for Specialty Medicines? Providers and patients fish for that delicate balance between access and abandonment. |
The Motley Fool March 31, 2011 Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
Pharmaceutical Executive April 1, 2012 Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
The Motley Fool February 24, 2011 Brian Orelli |
Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead. |
The Motley Fool March 25, 2011 Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
Pharmaceutical Executive June 1, 2014 Ben Comer |
Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy. |
Nursing Management March 2010 Becker & Schmidtke |
All along the watchtower: Suicide risk screening, a pilot study Patients will continue to die if healthcare organizations don't take action and appropriately assess patients at risk for suicide in general hospitals. |
Chemistry World June 14, 2012 Andrew Turley |
Good signs for Merck & Co insomnia pill In Phase III trials, insomnia drug candidate suvorexant performed well, reducing the time patients needed to fall asleep and increasing the total time sleeping, with some patients benefitting from the very first night of treatment. |
Pharmaceutical Executive January 1, 2013 Al Topin |
The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author. |
CIO October 29, 2015 Martha Heller |
Amgen uses algorithms to venture into digital healthcare A senior vice president of global marketing and commercial development, says she's working with the CIO to set up a digital healthcare organization that can help physicians better predict how patients will respond to therapies. |